It has been thoroughly demonstrated that sorafenib exhibits remarkable antitumor activity in HCC in vitro and in vivo, through targeting the RAF/MEK/EKR cascade [21,22]. This evidence concerns the gene RAF1 and hepatocellular carcinoma.